explore -WSS

explore

author：knowledge 2025-09-29 16:45:39 - browse：38

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： AI can decode, harness the power of the humane immune system

leisure time

WSS

FDA sets aggressive timeline for overhauling inspection procedures

FDA sets aggressive timeline for overhauling inspection procedures

3 questions for the future of Biden's cancer moonshot

Microsoft launches AI tool for clinical documentation through Epic

Histogen: Failed biotech offers rare public look inside

Update the Apgar Score to remove skin color

focus

explore

focus

Peter Hotez and the public health issue of online harassment

Immunocompromised patients offer clues on chronic Covid

Guidelines to prevent youth baseball injuries need more muscle

Printout prescription drug information shouldn’t go digital

Heart attack and stroke risk calculators need revising

To bolster infectious disease surveillance, genomics powerhouses team up

Novavax promises a turnaround & Lilly roils the obesity market

Dana Farber says 6 studies to be retracted and 31 corrected

United colonoscopy coverage change 'may cost lives,' doctors say

Why Charlie Gard's case is so disturbing to Americans

hotspot

Flu vaccine reformulation won't be easy, manufacturers warn

Colorectal cancer study finds potential in overlooked immune cell

Microsoft launches AI tool for clinical documentation through Epic

Dog Aging Project founders on what lies ahead after losing funding

FDA rejects Alnylam's heart disease treatment over insufficient data

3 questions for the future of Biden's cancer moonshot

hotspot

leisure time

explore

entertainment